Serum and cerebrospinal fluid S100B concentrations in patients with neurocysticercosis

Detalhes bibliográficos
Autor(a) principal: Lima, José Eduardo de Paula
Data de Publicação: 2006
Outros Autores: Walz, Roger, Tort, Adriano Bretanha Lopes, Souza, Diogo Onofre Gomes de, Portela, Luis Valmor Cruz, Bianchin, Marino Muxfeldt, Takayanagui, Osvaldo Massaiti, Leite, João Pereira
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFRGS
Texto Completo: http://hdl.handle.net/10183/21214
Resumo: The clinical manifestations of neurocysticercosis (NC) are varied and depend on the number and location of cysts, as well as on the host immune response. Symptoms usually occur in NC when cysticerci enter a degenerative course associated with an inflammatory response. The expression of brain damage markers may be expected to increase during this phase. S100B is a calcium-binding protein produced and released predominantly by astrocytes that has been used as a marker of reactive gliosis and astrocytic death in many pathological conditions. The aim of the present study was to investigate the levels of S100B in patients in different phases of NC evolution. Cerebrospinal fluid and serum S100B concentrations were measured in 25 patients with NC: 14 patients with degenerative cysts (D), 8 patients with viable cysts (V) and 3 patients with inactive cysts. All NC patients, except 1, had five or less cysts. In most of them, symptoms had been present for at least 1 month before sample collection. Samples from 8 normal controls (C) were also assayed. The albumin quotient was used to estimate the blood-brain barrier permeability. There were no significant differences in serum (P = 0.5) or cerebrospinal fluid (P = 0.91) S100B levels among the V, D, and C groups. These findings suggest that parenchymal changes associated with a relatively small number of degenerating cysts probably have a negligible impact on glial tissue.
id UFRGS-2_169d043de995b715c94d291deedbd983
oai_identifier_str oai:www.lume.ufrgs.br:10183/21214
network_acronym_str UFRGS-2
network_name_str Repositório Institucional da UFRGS
repository_id_str
spelling Lima, José Eduardo de PaulaWalz, RogerTort, Adriano Bretanha LopesSouza, Diogo Onofre Gomes dePortela, Luis Valmor CruzBianchin, Marino MuxfeldtTakayanagui, Osvaldo MassaitiLeite, João Pereira2010-04-24T04:15:46Z20060100-879Xhttp://hdl.handle.net/10183/21214000625970The clinical manifestations of neurocysticercosis (NC) are varied and depend on the number and location of cysts, as well as on the host immune response. Symptoms usually occur in NC when cysticerci enter a degenerative course associated with an inflammatory response. The expression of brain damage markers may be expected to increase during this phase. S100B is a calcium-binding protein produced and released predominantly by astrocytes that has been used as a marker of reactive gliosis and astrocytic death in many pathological conditions. The aim of the present study was to investigate the levels of S100B in patients in different phases of NC evolution. Cerebrospinal fluid and serum S100B concentrations were measured in 25 patients with NC: 14 patients with degenerative cysts (D), 8 patients with viable cysts (V) and 3 patients with inactive cysts. All NC patients, except 1, had five or less cysts. In most of them, symptoms had been present for at least 1 month before sample collection. Samples from 8 normal controls (C) were also assayed. The albumin quotient was used to estimate the blood-brain barrier permeability. There were no significant differences in serum (P = 0.5) or cerebrospinal fluid (P = 0.91) S100B levels among the V, D, and C groups. These findings suggest that parenchymal changes associated with a relatively small number of degenerating cysts probably have a negligible impact on glial tissue.application/pdfengBrazilian journal of medical and biological research = Revista brasileira de pesquisas médicas e biológicas. Ribeirão Preto, SP. Vol. 39, no. 1 (Jan. 2006), p. 129-135Proteínas S100NeurocisticercoseNeurocysticercosisS100BCerebrospinal fluidAlbumin quotientGlial markerSerum and cerebrospinal fluid S100B concentrations in patients with neurocysticercosisinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/otherinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSORIGINAL000625970.pdf000625970.pdfTexto completo (inglês)application/pdf484612http://www.lume.ufrgs.br/bitstream/10183/21214/1/000625970.pdf0c4d2b495b7bf0ec77ca07ff4a8ae5feMD51TEXT000625970.pdf.txt000625970.pdf.txtExtracted Texttext/plain28042http://www.lume.ufrgs.br/bitstream/10183/21214/2/000625970.pdf.txt40d27d449b77149fae4b44c5d576ae30MD52THUMBNAIL000625970.pdf.jpg000625970.pdf.jpgGenerated Thumbnailimage/jpeg1896http://www.lume.ufrgs.br/bitstream/10183/21214/3/000625970.pdf.jpg879bf84b5b603861fb3fe439dc72eb31MD5310183/212142021-11-20 05:55:46.194627oai:www.lume.ufrgs.br:10183/21214Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2021-11-20T07:55:46Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false
dc.title.pt_BR.fl_str_mv Serum and cerebrospinal fluid S100B concentrations in patients with neurocysticercosis
title Serum and cerebrospinal fluid S100B concentrations in patients with neurocysticercosis
spellingShingle Serum and cerebrospinal fluid S100B concentrations in patients with neurocysticercosis
Lima, José Eduardo de Paula
Proteínas S100
Neurocisticercose
Neurocysticercosis
S100B
Cerebrospinal fluid
Albumin quotient
Glial marker
title_short Serum and cerebrospinal fluid S100B concentrations in patients with neurocysticercosis
title_full Serum and cerebrospinal fluid S100B concentrations in patients with neurocysticercosis
title_fullStr Serum and cerebrospinal fluid S100B concentrations in patients with neurocysticercosis
title_full_unstemmed Serum and cerebrospinal fluid S100B concentrations in patients with neurocysticercosis
title_sort Serum and cerebrospinal fluid S100B concentrations in patients with neurocysticercosis
author Lima, José Eduardo de Paula
author_facet Lima, José Eduardo de Paula
Walz, Roger
Tort, Adriano Bretanha Lopes
Souza, Diogo Onofre Gomes de
Portela, Luis Valmor Cruz
Bianchin, Marino Muxfeldt
Takayanagui, Osvaldo Massaiti
Leite, João Pereira
author_role author
author2 Walz, Roger
Tort, Adriano Bretanha Lopes
Souza, Diogo Onofre Gomes de
Portela, Luis Valmor Cruz
Bianchin, Marino Muxfeldt
Takayanagui, Osvaldo Massaiti
Leite, João Pereira
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Lima, José Eduardo de Paula
Walz, Roger
Tort, Adriano Bretanha Lopes
Souza, Diogo Onofre Gomes de
Portela, Luis Valmor Cruz
Bianchin, Marino Muxfeldt
Takayanagui, Osvaldo Massaiti
Leite, João Pereira
dc.subject.por.fl_str_mv Proteínas S100
Neurocisticercose
topic Proteínas S100
Neurocisticercose
Neurocysticercosis
S100B
Cerebrospinal fluid
Albumin quotient
Glial marker
dc.subject.eng.fl_str_mv Neurocysticercosis
S100B
Cerebrospinal fluid
Albumin quotient
Glial marker
description The clinical manifestations of neurocysticercosis (NC) are varied and depend on the number and location of cysts, as well as on the host immune response. Symptoms usually occur in NC when cysticerci enter a degenerative course associated with an inflammatory response. The expression of brain damage markers may be expected to increase during this phase. S100B is a calcium-binding protein produced and released predominantly by astrocytes that has been used as a marker of reactive gliosis and astrocytic death in many pathological conditions. The aim of the present study was to investigate the levels of S100B in patients in different phases of NC evolution. Cerebrospinal fluid and serum S100B concentrations were measured in 25 patients with NC: 14 patients with degenerative cysts (D), 8 patients with viable cysts (V) and 3 patients with inactive cysts. All NC patients, except 1, had five or less cysts. In most of them, symptoms had been present for at least 1 month before sample collection. Samples from 8 normal controls (C) were also assayed. The albumin quotient was used to estimate the blood-brain barrier permeability. There were no significant differences in serum (P = 0.5) or cerebrospinal fluid (P = 0.91) S100B levels among the V, D, and C groups. These findings suggest that parenchymal changes associated with a relatively small number of degenerating cysts probably have a negligible impact on glial tissue.
publishDate 2006
dc.date.issued.fl_str_mv 2006
dc.date.accessioned.fl_str_mv 2010-04-24T04:15:46Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/other
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10183/21214
dc.identifier.issn.pt_BR.fl_str_mv 0100-879X
dc.identifier.nrb.pt_BR.fl_str_mv 000625970
identifier_str_mv 0100-879X
000625970
url http://hdl.handle.net/10183/21214
dc.language.iso.fl_str_mv eng
language eng
dc.relation.ispartof.pt_BR.fl_str_mv Brazilian journal of medical and biological research = Revista brasileira de pesquisas médicas e biológicas. Ribeirão Preto, SP. Vol. 39, no. 1 (Jan. 2006), p. 129-135
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFRGS
instname:Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
instname_str Universidade Federal do Rio Grande do Sul (UFRGS)
instacron_str UFRGS
institution UFRGS
reponame_str Repositório Institucional da UFRGS
collection Repositório Institucional da UFRGS
bitstream.url.fl_str_mv http://www.lume.ufrgs.br/bitstream/10183/21214/1/000625970.pdf
http://www.lume.ufrgs.br/bitstream/10183/21214/2/000625970.pdf.txt
http://www.lume.ufrgs.br/bitstream/10183/21214/3/000625970.pdf.jpg
bitstream.checksum.fl_str_mv 0c4d2b495b7bf0ec77ca07ff4a8ae5fe
40d27d449b77149fae4b44c5d576ae30
879bf84b5b603861fb3fe439dc72eb31
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)
repository.mail.fl_str_mv
_version_ 1801224711086014464